Sequent gets US FDA nod for its API Drug Manufacturing Facility at Mangalore

30 Apr 2013 Evaluate

Sequent Scientific (Sequent) has received an US FDA approval for its API drug manufacturing facility at Mangalore, Karnataka. The company’s Mangalore facility is ISO 9001 certified for Quality Management systems and ISO 14000 certified for Environment Management systems. This state-of-the-art facility engaged in the development and manufacture of APIs and API Intermediaries.

This facility has earlier received quality approval from TGA, Australia and certified by World Health Organisation, Geneva under its Prequalification's of Medicines Programme.

Sequent Scientific is an integrated pharmaceutical company with a global footprint headquartered in Bangalore, India which has presence in different pharmaceutical verticals including APIs, Animal Health, Analytical Services, CRAMS and specialty chemicals. Sequent is the world's largest producer of Anthelmintics and by far the strongest player in the Veterinary API business.

Sequent Scientific Share Price

201.70 9.60 (5.00%)
22-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1213.90
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 948.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.